Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk BioPharma DiveFoundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive Foundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Lilly bags FDA okay for Wegovy pill rival orforglipronNext: Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
